Ascendis Pharma, which is developing long-acting treatments for growth hormone deficiency, raised $108 million by offering 6 million shares (vs. 5 million originally planned) at $18, the high end of the $16 to $18 range. Ascendis Pharma will list on the NASDAQ under the symbol ASND. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as joint bookrunners on the deal.
The article Ascendis Pharma prices upsized IPO at $18, the high end of the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
